Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation

被引:19
|
作者
Dudek, Dariusz [1 ]
Rzeszutko, Lukasz [2 ]
Onuma, Yoshinobu [3 ]
Sotomi, Yohei [4 ]
Depukat, Rafal [2 ]
Veldhof, Susan [5 ]
Ediebah, Divine [5 ]
Staehr, Peter [6 ]
Zasada, Wojciech [7 ]
Malinowski, Krzysztof P. [8 ]
Kaluza, Grzegorz L. [9 ]
Serruys, Patrick W. [10 ]
机构
[1] Jagiellonian Univ, Inst Cardiol, Kopernika 17th Str, PL-31501 Krakow, Poland
[2] Univ Hosp, Krakow, Poland
[3] Erasmus MC, Thoraxctr, Rotterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands
[5] Abbott Vasc, Diegem, Belgium
[6] Abbott Vasc, Santa Clara, CA USA
[7] Krakow Cardiovasc Res Inst, Krakow, Poland
[8] Jagiellonian Univ, Coll Med, Krakow, Poland
[9] Cardiovasc Res Fdn, Orangeburg, NY USA
[10] Imperial Coll, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England
关键词
ABSORB; bioresorbable scaffold; vasomotion; TERM ENDOTHELIAL DYSFUNCTION; STENOTIC CORONARY-ARTERIES; MULTI-IMAGING MODALITY; VASCULAR SCAFFOLD; BALLOON ANGIOPLASTY; STENT; 2ND-GENERATION; OUTCOMES; SYSTEM; VASOCONSTRICTION;
D O I
10.1016/j.jcin.2016.12.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study investigated the vasomotor response to nitroglycerine (NTG) up to 5 years after ABSORB implantation. BACKGROUND There are no data regarding long-term vasomotor response after everolimus-eluting bioresorbable vascular scaffold ABSORB implantation. METHODS We performed quantitative coronary angiography of the scaffolded and proximal and distal adjacent segments of patients from ABSORB Cohort B study before and after 200 mg of intracoronary NTG at 2, 3, and 5 years of follow-up. The mean changes of maximal and mean lumen diameters in the scaffolded and adjacent segments were calculated. RESULTS The mean in-scaffold lumen diameter change in response to NTG showed a trend to increase over time with absolute values of 0.03 +/- 0.09 mm, 0.05 +/- 0.12 mm, and 0.07 +/- 0.08 mm at 2, 3, and 5 years, respectively (p = 0.40). The maximal in-scaffold lumen diameter change significantly increased with values of 0.03 +/- 0.14 mm, 0.06 +/- 0.16 mm, and 0.11 +/- 0.1 mm at 2, 3, and 5 years, respectively (p = 0.03). The normalized mean lumen diameter change after NTG in the scaffold relative to the adjacent segments was 51.9 +/- 54.8% at 5 years of follow-up (p = 0.60). CONCLUSIONS Although there was a numerical increase of the vasomotor response to NTG after ABSORB implantation measured by quantitative coronary angiography with mean lumen diameter, the change was not statistically significant. However, the maximal lumen diameter changes increased over time from 2 to 5 years and attained statistical significance. The vasomotor response to NTG after ABSORB implantation moderately trended to increase, which is consistent with the progressive degradation and bioresorption of the scaffold, but the degree of vasomotor response remained lower in comparison with adjacent segments. (C) 2017 by the American College of Cardiology Foundation.
引用
收藏
页码:786 / 795
页数:10
相关论文
共 50 条
  • [1] Five-year follow-up of patients who underwent everolimus-eluting bioresorbable scaffold implantation
    Wiebe, Jens
    Hofmann, Felix J.
    Doerr, Oliver
    Bauer, Timm
    Boeder, Niklas
    Liebetrau, Christoph
    Blachutzik, Florian
    Moellmann, Helge
    Elsaesser, Albrecht
    Achenbach, Stephan
    Hamm, Christian W.
    Nef, Holger M.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 97 (01) : 56 - 62
  • [2] Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents RESPONSE
    Zhang, Xin-Lin
    Xu, Biao
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (11) : 829 - 829
  • [3] Everolimus-eluting bioresorbable coronary scaffold in Asian patients: A 2-year follow-up
    Azad, Muhammad Abdul Salam
    Gul, Uzma
    Javed, Asim
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2020, 70 (12) : 2281 - 2284
  • [4] Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold
    Meneguz-Moreno, Rafael Alexandre
    Costa Junior, Jose de Ribamar
    Britto Moscoso, Freddy Antonio
    Staico, Rodolfo
    Leite Tanajura, Luiz Fernando
    Centemero, Marinella Patrizia
    Chaves, Aurea Jacob
    Leao de Sousa Abizaid, Andrea Claudia
    de Moraes Rego e Sousa, Amanda Guerra
    Cunha Abizaid, Alexandre Antonio
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2017, 108 (02) : 109 - 114
  • [5] Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial
    Onuma, Yoshinobu
    Sotomi, Yohei
    Shiomi, Hiroki
    Ozaki, Yukio
    Namiki, Atsuro
    Yasuda, Satoshi
    Ueno, Takafumi
    Ando, Kenji
    Furuya, Jungo
    Igarashi, Keiichi
    Kozuma, Ken
    Tanabe, Kengo
    Kusano, Hajime
    Rapoza, Richard
    Popma, Jeffrey J.
    Stone, Gregg W.
    Simonton, Charles
    Serruys, Patrick W.
    Kimura, Takeshi
    EUROINTERVENTION, 2016, 12 (09) : 1090 - 1101
  • [6] OCT Assessment of the Long-Term Vascular Healing Response 5 Years After Everolimus-Eluting Bioresorbable Vascular Scaffold
    Karanasos, Antonios
    Simsek, Cihan
    Gnanadesigan, Muthukarrupan
    van Ditzhuijzen, Nienke S.
    Freire, Raphael
    Dijkstra, Jouke
    Tu, Shengxian
    Van Mieghem, Nicolas
    van Soest, Gijs
    de Jaegere, Peter
    Serruys, Patrick W.
    Zijlstra, Felix
    van Geuns, Robert-Jan
    Regar, Evelyn
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (22) : 2343 - 2356
  • [7] Endothelial vasomotor function after everolimus-eluting stent implantation
    Homs, S.
    Roura, G.
    Gomez-Lara, J.
    Ferreiro, J. L.
    Romaguera, R.
    Sanchez-Elvira, G.
    Teruel, L.
    Gomez-Hospital, J. A.
    Cequier, A.
    EUROPEAN HEART JOURNAL, 2013, 34 : 546 - 546
  • [8] Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: A three-years follow-up
    Anadol, Remzi
    Dimitriadis, Zisis
    Polimeni, Alberto
    Wendling, Franziska
    Goenner, Svenja
    Ullrich, Helen
    Lorenz, Liv
    Weissner, Melissa
    Munzel, Thomas
    Gori, Tommaso
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2018, 69 (1-2) : 3 - 8
  • [9] A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis 5-Year Follow-Up
    Serruys, Patrick W.
    Ormiston, John
    van Geuns, Robert-Jan
    de Bruyne, Bernard
    Dudek, Dariusz
    Christiansen, Evald
    Chevalier, Bernard
    Smits, Pieter
    McClean, Dougal
    Koolen, Jacques
    Windecker, Stephan
    Whitbourn, Robert
    Meredith, Ian
    Wasungu, Luc
    Ediebah, Divine
    Veldhof, Susan
    Onuma, Yoshinobu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (07) : 766 - 776
  • [10] Vasomotor function and optical coherence tomography follow-up 4 years after Fantom bioresorbable scaffold implantation: A case report
    Koltowski, Lukasz
    Zaleska, Martyna
    Maksym, Jakub
    Kochman, Janusz
    CARDIOLOGY JOURNAL, 2023, 30 (04) : 671 - 672